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A B S T R A C T
An endogenous anticancer agent, 15-deoxy -Δ12,14-prostaglandin J2 (15d-PGJ2) induces apoptosis in the
chemoresistant renal cell carcinoma (RCC). Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear
receptor for 15d-PGJ2, and mediates the cytotoxicity of 15d-PGJ2 in many cancerous cells. However, 15d-PGJ2
induces apoptosis independently of PPARγ in human RCC cell line such as Caki-2. In the present study, we
found that 15d-PGJ2 ameliorated the chemoresistance to one of anthracycline antibiotics, doxorubicin, in Caki-
2 cells. Doxorubicin alone exhibited weak cytotoxicity at the concentrations eﬀective for other cancer cells such
as Hela cells. In addition, it did not activate caspase 3. However, the cytotoxicity of doxorubicin was increased
remarkably and accompanied with the caspase- 3 activation in the presence of 15d-PGJ2. Doxorubicin alone
damaged plasma membrane, and the combined application of 15d-PGJ2 with doxorubicin increased the
membrane permeability slightly. PPARγ was involved in neither the anti-tumor activity nor the synergistic eﬀect
of 15d-PGJ2. 15d-PGJ2 induces apoptosis in Caki-2 cells via suppressing the phosphoinositide 3-kinase (PI3K)-
Akt pathway. The eﬀect of PI3K inhibitor on the cytotoxicity of doxorubicin was additive, but not synergistic.
Although the PI3K inhibitor mimicked the cytotoxicity of 15d-PGJ2, it might not be involved in the synergism
between 15d-PGJ2 and doxorubicin. In conclusion, 15d-PGJ2 enhanced the chemosensitivity of doxorubicin via
the pathway independent of PPARγ and PI3K.
1. Introduction
Renal cell carcinomas (RCCs) account for approximately 2% of
adult carcinomas. Despite extensive evaluation of many diﬀerent
treatment modalities, advanced metastatic RCC remains highly resis-
tant to radiotherapy and chemotherapy [1]. Clear cell RCC accounts for
the majority of RCC cases [2] and one-third of the patients present with
metastases at initial diagnosis. Nearly half of all patients with RCC die
within 5 years of diagnosis and 5-year survival for those with
metastatic disease is < 10% [3]. Chemotherapeutic agents, such as
gemcitabine, 5-ﬂuorouracil (5-FU), capecitabine and vinblastine, ex-
hibit clinical beneﬁts partially [4]. Based on the immunogenicity of
RCCs, the potency of cytokines, mainly interleukin 2 and/or interferon-
α, have been reported by several clinical studies [5,6]. The treatment of
RCCs has been modiﬁed by chemotherapeutic agents, such as tyrosine
kinase inhibitors (sunitinib, sorafenib, pazopanib, and axitinib), the
anti-VEGF monoclonal antibody (bevacizumab) administered with
interferon α) and mammalian target of rampamycin (mTOR) inhibitors
(everolimus and temsirolimus) [7]. However, despite these novel
therapies, the clinical outcome of patients with RCC remains poor [4].
To overcome the resistance of RCCs to chemotherapy, we have
studied combinations of chemotherapy with new agents.
Responsiveness of RCCs such as Caki-2 cell for conventional anticancer
agents such as 5-FU, camptothecin (CPT) and etoposide (VP16) was
lower than that of other types of cancer such as Hela cells [8–12]. CPT
and VP16 are inhibitors of DNA topoisomerase I and II, respectively.
DNA topoisomerases resolve topological constraints that may arise
from DNA strand separation and are therefore important for transcrip-
tion and replication [13]. Previously, we have reported that 15‑deoxy-
Δ12,14‑prostaglandin J2 (15d-PGJ2) enhanced the anti-tumor activity of
camptothecin, [11] and etoposide [12]. 15d-PGJ2 is an endogenous
anticancer agent. Although peroxisome proliferator-activated receptor-
γ (PPARγ) is a nuclear receptor for 15d-PGJ2[14,15], it does not
mediate the cytotoxicity of 15d-PGJ2 in RCCs [16,17]. Furthermore,
synergistic toxicities of 15d-PGJ2 with topoisomerases were also
independent from PPARγ.
In cancer, the phosphoinositide 3-kinase (PI3K)/Akt and mTOR
pathway is activated via multiple mechanisms [18]. Since the PI3K
http://dx.doi.org/10.1016/j.bbrep.2016.11.004
Received 20 June 2016; Received in revised form 4 November 2016; Accepted 8 November 2016
⁎ Corresponding author.
E-mail address: yagami@himeji-du.ac.jp (T. Yagami).
Biochemistry and Biophysics Reports 9 (2017) 61–66
2405-5808/ © 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the  CC BY license (http://creativecommons.org/licenses/by/4.0/).
Available online 17 November 2016
crossmark
signaling is hyperactivated in RCCs, this pathway is one of targeted
therapies [19]. 15d-PGJ2 inhibits proliferation of primary astrocytes
[20] and neuroblastoma x DRG neuron hybrid cell line N18D3 [21] via
down-regulating PI3K-Akt pathway. Previously, we have reported that
the PI3K/Akt signaling mediated the cytotoxicity of 15d-PGJ2[17].
Here, we found that a PI3K inhibitor, LY294002, mimicked the
cytotoxicity of 15d-PGJ2. Furthermore, 15d-PGJ2 enhanced the anti-
tumor activity of the anthracycline antibiotic, doxorubicin, synergisti-
cally. In the present study, we ascertained whether the PI3K inhibitor
enhanced the anti-tumor activity of doxorubicin.
2. Materials and methods
2.1. Cell lines and cell culture
The Caki-2 human RCC cell line was obtained from Summit
Pharmaceuticals International (Tokyo, Japan). The Caki-2 cells were
routinely cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum, 50 mg/l penicillin G and 50 mg/l streptomycin
(Invitrogen, Tokyo, Japan), at 37 °C in a 5% CO2-95% room air.
2.2. Reagents
15d-PGJ2 was obtained from Cayman Chemicals (Ann Arbor, MI;
Cabru, Milan, Italy). Doxorubicin was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). GW9662 was obtained from
Sigma-Aldrich (St. Louis, MO, USA). 3-(4,5-dimethylthiazol-2-yl)−2,5-
diphenyl tetrazolium bromide dye (MTT) and propidium iodide (PI)
were purchased from Dojindo Laboratories (Kumamoto, Japan).
LY294002 was purchased from Cell Signaling Technology (Boston,
MA). The protein concentration was measured using the BCA protein
assay reagent obtained from Pierce (Rockford, IL).
2.3. Cell viability analysis
15d-PGJ2 was dissolved in culture medium after evaporation of
vehicle. Two diﬀerent methods were employed for assessment of cell
viability as previously reported. First, the MTT reduction assay
reﬂecting mitochondrial succinate dehydrogenase activity was em-
ployed. The cells were seeded on a 96-well tissue culture plate at
10,000 cells/cm2 and incubated for 24 h prior to drug exposure. The
cells were incubated with 15d-PGJ2 and doxorubicin at the indicated
concentrations. After 20 h or 24 h, the cells were incubated with MTT
solution (0.1 mg/ml in phosphate-buﬀered saline) for an additional 3 h
at 37 °C. The MTT solution was then aspirated oﬀ. To dissolve the
formazan crystals formed in viable cells, 100 μl dimethyl sulfoxide was
added to each well. Absorbance was measured at 570 nm using a
spectrophotometer (iMark Microplate Reader, Bio-Rad Laboratories,
Hercules, CA, USA). Second, Cell death was also measured by manually
counting the percentage of neurons that stained with propidium iodide
(PI, 0.1 µg/ml). The cells were seeded on a 24-well tissue culture plate
at 10,000 cells/cm2 and incubated for 24 h prior to drug exposure.
Nuclei stained with PI were counted from 12 ﬁelds with data expressed
as percentage PI-stained cells normalized to the vehicle-treated group.
2.4. Fluorimetric assay of caspase-3 activity
Caspase-3 activity was assessed using a Caspase-3 Fluorimetric
Assay kit, (Sigma-Aldrich), according to the manufacturer's instruc-
tions. Brieﬂy, the cells were seeded into 96-well plates at a density of
10,000 cells/cm2 and incubated with 20 μM 15d-PGJ2 and 1 μM
doxorubicin for 24 h. After exposure to the drugs for 24 h, the super-
natants were aspirated and the cells were harvested with lysis buﬀer
[50 mM HEPES (pH 7.4), 5 mM CHAPS and 5 mM DTT]. The reaction
buﬀer, including acetyl-Asp-Glu-Val-Asp-7-amido4-methylcoumarin
(Ac-DEVD-AMC), a caspase-3 speciﬁc substrate, was added to the
wells and the production of AMC was sequentially detected with a
CytoFluor® Plate reader (MTX Lab Systems, Vienna, VA, USA) at an
excitation wavelength of 360 nm and at an emission wavelength of
460 nm. The enzyme activities were determined as initial velocities
expressed as nmol AMC/min/ml and were then corrected by the
quantity of protein in each well detected by bicinchoninic acid protein
assays (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
2.5. Statistical analysis
Data are given as means ± SE (n=numbers of observations). We
performed two experiments at least on diﬀerent days, and conﬁrmed
their reproducibility. We analyzed observations obtained on the same
day, and presented the typical experimental results among indepen-
dent ones on diﬀerent days to minimize experimental errors. Data were
statistically analyzed with the Student's t-test for comparison with the
control group. Data on various drugs were statistically analyzed by two-
way ANOVA followed by Dunnett's test for comparison between the
groups.
3. Results
3.1. 15d-PGJ2 exacerbated the doxorubicin-disrupted morphology in
Caki-2 cells
As shown in Fig. 1, we evaluated cytotoxicities of doxorubicin and
15d-PGJ2 on Caki-2 cells with morphology and MTT-reducing activity
(Fig. 1). In control culture, most Caki-2 cells were bipolar. Several cells
were multipolar and have protrusions. Caki-2 cells have elongated
shapes, and grow attached to a substrate (Fig. 1A). Doxorubicin
exhibited weak toxicities at 1 μM alone (Fig. 1B). It decreased bipolar
cells and increased polygonal cells (Fig. 1A). 15d-PGJ2 also reduced
cell viability slightly at 20 μM alone (Fig. 1B). In contrast to doxor-
ubicin, 15d-PGJ2 kept Caki-2 cells elongated shape, increased protru-
sions and made focal contacts clear (Fig. 1A). Combination of
doxorubicin with 15d-PGJ2 caused cell death markedly (Fig. 1B). In
the two anti-cancer agents-treated culture, Caki-2 cells were spherical
in shape and peeled in suspension without attaching to a substrate.
Filamentous protrusions were extended from residual cells (Fig. 1A).
PPARγ do not mediate the anti-tumor activity of 15d-PGJ2 in Caki-
2 cells [11,12,17]. We conﬁrmed that PPARγ antagonist, GW9662, did
not rescued Caki-2 cells from the cytotoxicity of 15d-PGJ2 (Fig. 1C).
Similarly, GW9662 did not aﬀected viability of Caki-2 cells in doxor-
ubicin-treated Caki-2 cells regardless 15d-PGJ2.
3.2. 15d-PGJ2 and doxorubicin induced apoptosis synergistically in
Caki-2 cells
15d-PGJ2-induced apoptosis is accompanied with the caspase
activation in Caki-2 cells. We conﬁrmed that 20 μM 15d-PGJ2 activated
caspase-3 signiﬁcantly. On the other hand, 1 μM doxorubicin did not
activate caspase-3. However, combination of doxorubicin with 15d-
PGJ2 enhanced caspase-3 activity markedly (Fig. 2A).
Apoptosis is also characterized by PI staining of nuclei. PI is
membrane impermeable and generally excluded from viable cells.
When plasma membrane is damaged, PI is incorporated into cells
and binds to DNA by intercalating between the bases in the nuclei. PI is
commonly used for identifying dead cells in a population and as a
counterstain in multicolor ﬂuorescent techniques. We have not suc-
ceeded in detecting PI-stained nuclei of RCC treated with 1 μM
doxorubicin and/or 20 μM 15d-PGJ2 (data not shown). Therefore, we
performed PI staining of RCC treated with 5 μM doxorubicin and/or
20 μM 15d-PGJ2 (Fig. 2B and C). Little PI-positive cell was detected in
control culture (Fig. 2B and C). PI-positive cells were increased in the
doxorubicin-treated culture, but not in the 15d-PGJ2-treated one.
Doxorubicin enhanced the PI-staining of 15d-PGJ2-treated cells
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Fig. 1. 15d-PGJ2exacerbated the doxorubicin-disrupted morphology in Caki-2 cells.
Caki-2 was treated with 1 μM doxorubicin (Dox) in the absence or presence of 20 μM
15d-PGJ2 for 24 h. (A) Morphologies were photographed by phase contrast. Scale
bar=100 µm. (B) Cell viabilities were determined by MTT reducing activity. (C) Caki-2
cells were treated with 1 μM doxorubicin and/or 20 μM 15d-PGJ2 in the absence (open
columns) or presence (ﬁlled columns) of 10 μM GW9662. Cell viabilities were deter-
mined by MTT reducing activity. Data are expressed as means ± SE. (n =6). **P < 0.01,
compared with control. ##P < 0.01, compared with 15d-PGJ2 alone.
Fig. 2. 15d-PGJ2 and doxorubicin induced apoptosis synergistically in Caki-2 cells.
Capase-3: Caki-2 cells were treated with 1 μM doxorubicin in the absence or presence of
20 μM 15d-PGJ2. Caspase-3 activities were determined as initial velocities (A). Data are
expressed as means ± SE. (n=3). *P < 0.05, compared with control. ##P < 0.01,
compared with 15d-PGJ2 alone. PI staining: Caki-2 was treated with 5 μM doxorubicin
in the absence or presence of 20 μM 15d-PGJ2 for 24 h. PI-stained Caki-2 cells were
photographed (B) and counted (C). Scale bar=100 µm. Cell death is expressed as % (PI-
stained cell numbers/total cell numbers). Data are expressed as means ± SE. (n=12).
Since PI-stained cells were not detected in the control culture, signiﬁcant diﬀerence
compared with the control culture could not be tested.
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slightly, but not signiﬁcant.
3.3. A PI3K inhibitor increased the cytotoxicity of doxorubicin in
Caki-2 cells additively
Previously, we have reported that Akt was involved in the cytotoxi-
city of 15d-PGJ2 [17]. As shown in Fig. 4A, we ascertained whether
PI3K was involved in the synergy between 15d-PGJ2 and doxorubicin.
The cytotoxicity of doxorubicin and a PI3K inhibitor, LY294002, on
Caki-2 cells was evaluated with morphology and MTT-reducing activ-
ity. In control culture, most Caki-2 cells were bipolar. Several cells were
multipolar and have protrusions. Caki-2 cells have elongated shapes,
and grow attached to a substrate (Fig. 3A). The PI3K inhibitor,
LY294002, induced cell death in a concentration-dependent manner
(Fig. 3B). The PI3K inhibitor, LY294002, reduced the density of Caki-2
cells. In contrast to 15d-PGJ2, LY294002 did not degenerate morphol-
ogy of Caki-2 cells signiﬁcantly. In the presence of LY294002,
doxorubicin reduced the density of Caki-2 cells and degenerated cell
morphology markedly. However, eﬀects of LY294002 on the cytotoxi-
city of doxorubicin was additive at the indicated concentrations, but
not synergistic (Fig. 3A and B).
3.4. Doxorubicin did not condense chromatin in Caki-2 cells
Apoptosis is accompanied with chromatin condensation. As shown
in Fig. 4A, 15d-PGJ2 condensed chromatin in RCCs [17] and neurons
[22]. Doxorubicin acts the anti-cancer agent via inhibiting topoisome-
rase II. Previously, we have reported that a topoisomerase I inhibitor,
camptothecin, condensed chromatin as well as 15d-PGJ2 [11]. A
topoisomerase II inhibitor, etoposide (VP-16), -induced cell death
[12] was also accompanied with chromatin condensation in Caki-2
cells (Fig. 4A). Furthermore, 20 μM 15d-PGJ2 increased the etoposide-
condensed chromatin markedly. However, doxorubicin did not in-
crease chromatin condensation regardless of 20 μM 15d-PGJ2 under
the cytotoxic condition (1 μM, 24 h).
3.5. A PI3K inhibitor increased the cytotoxicity of doxorubicin in
Caki-2 cells additively
Previously, we have reported the synergistic eﬀects of 15d-PGJ2 on
anti-tumor activities of camptothecin [11] and etoposide [12].
Therefore, we ascertained whether PI3K was involved the synergy
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Fig. 3. Additive eﬀect of a PI3-K inhibitor on the anti-tumor activity of doxorubicin in
Caki-2 cells. Caki-2 cells were treated with LY294002 at the indicated concentrations in
the absence (open columns) or presence (ﬁlled columns) of 1 μM doxorubicin for 24 h.
(A) Morphologies of RCCs treated with 30 μM LY294002 and/or 1 μM doxorubicin were
photographed by phase contrast. 30 μM LY294002 1 μM doxorubicin Scale bar=50 µm.
(B) Cell viabilities were determined by MTT reducing activity. Data are expressed as
means ± SE. (n=6). **P < 0.01, compared with control. ##P < 0.01, compared with
LY294002 alone.
Fig. 4. Additive eﬀect of and 15d-PGJ2 and PI3-K inhibitor on the anti-tumor activity of
topoisomerase inhibitors in Caki-2 cells. (A) Caki-2 cells were assayed for nuclear
chromatin condensation following treatment for 20 h (open columns) or 24 h (ﬁlled
columns) with 20 μM 15d-PGJ2 in the absence or presence of 70 μM VP-16. Data are
expressed as means ± SE. (n=12). Since chromatin-condensed nucleus were not detected
in the control culture at 20 h, signiﬁcant diﬀerence compared with the control culture
could not be tested. *P < 0.05, compared with control (24 h). (B) Caki-2 cells were treated
with LY294002 at the indicated concentrations in the absence (circles) or presence of
1 μM camptothecin (triangles) or 30 μM VP-16 (squares) for 24 h. Cell viabilities were
determined by MTT reducing activity. Data are expressed as means ± SE. (n=6). **P <
0.01, compared with control. ##P < 0.01, compared with camptothecin or VP-16 alone.
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between 15d-PGJ2 and the two topoisomerase inhibitors (Fig. 4B). At
the concentration less than 10 μM, LY294002 did not appear to aﬀect
the cytotoxicity of camptothecin and etoposide. At the concentration
more than 30 μM, the PI3K inhibitor enhanced cytotoxicities of the two
topoisomerase inhibitors additively, but not synergistically.
4. Discussion
In the present study, we provided the ﬁrst evidence that 15d-PGJ2
enhanced anti-tumor activities of the anthracycline antibiotic, doxor-
ubicin, in human renal cell carcinoma, Caki-2 cells. Doxorubicin
degenerated morphologies of Caki-2 cells in a diﬀerent fashion from
15d-PGJ2. 15d-PGJ2 targets the cytoskeleton protein, actin, resulting
in alteration of cell morphologies [23]. Actin is one of adapter proteins,
which mediates the intracellular domain of integrin binds to the
cytoskeleton. Since this integrin-adapter protein (actin) -cytoskeleton
complex forms the basis of a focal adhesion, it was likely that 15d-PGJ2
increased protrusions and made focal adhesion clear. In contrast to
15d-PGJ2, doxorubicin appeared to enlarge the area of cytosol in
comparison with that of nucleus. Doxorubicin altered morphologies of
Caki-2 cells similarly to etoposide (VP-16) in accordance with the fact
that they are topoisomerase II inhibitors [12].
15d-PGJ2-induced apoptosis was accompanied with chromatin
condensation and caspase- 3 activation, and restored by co-treatment
with a pan-caspase inhibitor, Z-VAD-FMK [17]. In the present study,
we conﬁrmed that 15d-PGJ2 activated caspase-3 and induced apoptosis
in Caki-2 cells. In addition, 15d-PGJ2 enhanced the doxorubicin-
activated caspase- 3 synergistically. Doxorubicin has also been reported
to condense chromatin in myeloma and leukemia [24]. However, in
Caki-2 cells, VP16 caused chromatin condensation, but doxorubicin did
not under the condition exhibiting cytotoxicity. Topoisomerase II is the
common target for doxorubicin and VP16. However, doxorubicin is the
anthracycline antibiotic, whereas VP16 is the alkaloid derived from
plants. Because of diﬀerent basic structures, the two inhibitors did not
always exhibit cytotoxicity in the same fashion in Caki-2 cells. To cite
another case, doxorubicin elevated the permeability of plasma mem-
brane, but etoposide did not under the condition exhibiting cytotoxicity
(data not shown).
In comparison with normal tissues, 15d-PGJ2 are markedly de-
creased in tumors and metastatic breast tissues, suggesting that the
reduction of 15d-PGJ2 aﬀects the development of cancer and its
progression to metastasis [25]. 15d-PGJ2 possesses opposite functions,
cytoprotective activities and proapoptotic properties in many cancer
cell lines [26]. 15d-PGJ2 induces apoptosis PPARγ-dependently in
neuroblastoma [27] and hepatic myoﬁbroblasts [28], whereas PPARγ-
independently in colorectal cancer [29], breast cancer [30], hepatocel-
lular carcinoma [31] and prostate and bladder carcinoma [32]. We
conﬁrmed that PPARγ did not mediate the anti-tumor activity of 15d-
PGJ2 in RCCs [11,12,16,17]. In addition, PPARγ antagonist, GW9662,
did not suppressed the combined cytotoxicity of 15d-PGJ2 and
doxorubicin. These ﬁndings suggested that PPARγ did not mediate
synergistic eﬀects of 15d-PGJ2 and doxorubicin.
Previously, we have reported that the PI3K-Akt signaling played an
important role in the cytoprotection and proliferation of RCCs [17].
15d-PGJ2 markedly decreased the phosphorylation of Akt. The Akt
inhibitor showed cytotoxicity with a low IC50 value, suggesting that
15d-PGJ2 exerted cytotoxicity via the inactivation of Akt. In the present
study, we conﬁrmed that the PI3K inhibitor mimicked the anti-tumor
activity of 15d-PGJ2. However, we could not detect the synergistic
eﬀect between doxorubicin and PI3K inhibitor. In addition, the PI3K
inhibitor did not enhanced cytotoxicities of another topoisomerase II
inhibitor, etoposide, and a topoisomerase inhibitor I, camptothecin.
15d-PGJ2 has been reported to inhibit the ubiquitin-proteasome path-
way in neuroblastoma cells [33]. The proteasome inhibitor potentiates
the growth inhibition by doxorubicin in leukemia [24]. In Caki-2 cells,
we could not rule out the possibility that 15d-PGJ2 might potentiate the
anti-proliferative eﬀect of doxorubicin via suppression of the ubiquitin-
proteasome pathway. Thus, 15d-PGJ2 increased the chemosensitivity
of doxorubicin independently of PPARγ and PI3K. Further studies are
required to identify targets for 15d-PGJ2, which reduces the chemore-
sistance of doxorubicin.
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